Island Pharmaceuticals Ltd (ILA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Island Pharmaceuticals Ltd (ILA) has a cash flow conversion efficiency ratio of -0.237x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.69 Million ≈ $-1.20 Million USD) by net assets (AU$7.16 Million ≈ $5.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Island Pharmaceuticals Ltd fund operations to measure how many days the company can operate on defensive assets alone.
Island Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Island Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Island Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Island Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sai Gon Ground Services JSC
VN:SGN
|
-0.056x |
|
Africa Energy Corp
V:AFE
|
-0.016x |
|
EML Payments Ltd
F:A8Y1
|
-0.016x |
|
TagMaster AB Series B
ST:TAGM-B
|
0.129x |
|
GAMING INNOVATION DL 1
F:GI11
|
-0.578x |
|
Handok
KO:002390
|
-0.058x |
|
Invesco High Income Trust II
NYSE:VLT
|
0.019x |
|
d1000 Varejo Farma Participações S.A
SA:DMVF3
|
0.180x |
Annual Cash Flow Conversion Efficiency for Island Pharmaceuticals Ltd (2019–2024)
The table below shows the annual cash flow conversion efficiency of Island Pharmaceuticals Ltd from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see ILA stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | AU$7.16 Million ≈ $5.06 Million |
AU$-2.77 Million ≈ $-1.96 Million |
-0.387x | +81.44% |
| 2023-12-31 | AU$1.52 Million ≈ $1.07 Million |
AU$-3.16 Million ≈ $-2.24 Million |
-2.084x | -37.34% |
| 2022-12-31 | AU$1.79 Million ≈ $1.26 Million |
AU$-2.71 Million ≈ $-1.92 Million |
-1.517x | -248.92% |
| 2021-12-31 | AU$4.32 Million ≈ $3.06 Million |
AU$-1.88 Million ≈ $-1.33 Million |
-0.435x | -196.57% |
| 2020-12-31 | AU$6.40 Million ≈ $4.53 Million |
AU$-938.24K ≈ $-663.86K |
-0.147x | -702.06% |
| 2019-12-31 | AU$-657.00 ≈ $-464.87 |
AU$-16.00 ≈ $-11.32 |
0.024x | -- |
About Island Pharmaceuticals Ltd
Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East,… Read more